Abstract
The majority of patients with lung cancer present with advanced stage which contributes to death of more people than any other malignancy in the world. The discovery of a number of lung cancer-molecular alterations contributes to uniquely targeted therapies with specific inhibitors for non-small cell lung cancer such as erlotinib, gefitinib and crizotinib. Pemetrexed has statistically shown significantly reduced adverse side effects of drug compared with docetaxel. V1801, an analog of gefitinib may overcome gefitinib resistance in patients with non-small cell lung cancer. Thymosin α1, an immunomodulator significantly improves patient’s quality of life by enhancing T-cell function, stimulation of Tcell maturation and differentiation. Various novel compounds and chemotherapeutics were introduced in 2013 patents such as taxane, quinazoline, arylamino purine, benzodiazepine, pyrrolopyrimidine, nitrobenzamide, cyclopropane amide, 4-iodo-3-nitrobenzamide, heteroaryl (alkyl) dithiocarbamate, and histone deacetylase in treating non-small-cell lung cancer and piperidine, piperazine, picoplatin, and arsenic trioxide in treating small-cell lung cancer.
Keywords: Cancer, chemotherapy, lung, lung cancer-molecular alterations, related patents, treatment.
Recent Patents on Anti-Cancer Drug Discovery
Title:Lung Cancer Chemotherapy, New Treatment and Related Patents
Volume: 9 Issue: 3
Author(s): Attapon Cheepsattayakorn and Ruangrong Cheepsattayakorn
Affiliation:
Keywords: Cancer, chemotherapy, lung, lung cancer-molecular alterations, related patents, treatment.
Abstract: The majority of patients with lung cancer present with advanced stage which contributes to death of more people than any other malignancy in the world. The discovery of a number of lung cancer-molecular alterations contributes to uniquely targeted therapies with specific inhibitors for non-small cell lung cancer such as erlotinib, gefitinib and crizotinib. Pemetrexed has statistically shown significantly reduced adverse side effects of drug compared with docetaxel. V1801, an analog of gefitinib may overcome gefitinib resistance in patients with non-small cell lung cancer. Thymosin α1, an immunomodulator significantly improves patient’s quality of life by enhancing T-cell function, stimulation of Tcell maturation and differentiation. Various novel compounds and chemotherapeutics were introduced in 2013 patents such as taxane, quinazoline, arylamino purine, benzodiazepine, pyrrolopyrimidine, nitrobenzamide, cyclopropane amide, 4-iodo-3-nitrobenzamide, heteroaryl (alkyl) dithiocarbamate, and histone deacetylase in treating non-small-cell lung cancer and piperidine, piperazine, picoplatin, and arsenic trioxide in treating small-cell lung cancer.
Export Options
About this article
Cite this article as:
Cheepsattayakorn Attapon and Cheepsattayakorn Ruangrong, Lung Cancer Chemotherapy, New Treatment and Related Patents, Recent Patents on Anti-Cancer Drug Discovery 2014; 9 (3) . https://dx.doi.org/10.2174/1574892809666140520120806
DOI https://dx.doi.org/10.2174/1574892809666140520120806 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ricin and Saporin: Plant Enzymes for the Research and the Clinics
Current Chemical Biology Phenothiazine Derivatives as Potential Antiproliferative Agents: A Mini- Review
Mini-Reviews in Organic Chemistry Pyrrolo[2,1-c][1,4]benzodiazepine as a Scaffold for the Design and Synthesis of Anti- Tumour Drugs
Anti-Cancer Agents in Medicinal Chemistry Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets Angiogenesis as a therapeutic target in breast cancer
Mini-Reviews in Medicinal Chemistry Chinese Medicine: A Novel Therapeutic Option for Pancreatic Cancer
Current Signal Transduction Therapy A Novel Feature-Significance Based k-Nearest Neighbour Classification Approach for Computer Aided Diagnosis of Lung Disorders
Current Medical Imaging Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets Differential Expressions of Matrix Metalloproteinases, A Disintegrin and Metalloproteinases, and a Disintegrin and Metalloproteinases with Thrombospondin Motifs and their Endogenous Inhibitors Among Histologic Subtypes of Lung Cancers
Anti-Cancer Agents in Medicinal Chemistry Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Potential Utility of Mycobacterium w Vaccine in Control of Tuberculosis
Current Respiratory Medicine Reviews Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Anticancer Activity of 2,4,5-triaryl Imidazole Derivatives
Letters in Drug Design & Discovery Marine Peptides and Related Compounds in Clinical Trial+
Anti-Cancer Agents in Medicinal Chemistry Heterocyclic Curcumin Derivatives of Pharmacological Interest: Recent Progress
Current Topics in Medicinal Chemistry Novel Classes of Dimer Antitumour Drug Candidates
Current Pharmaceutical Design ABC Transporters and the Blood-Brain Barrier
Current Pharmaceutical Design